Investment-happy German drug giant Boehringer Ingelheim Pharmaceuticals Inc. is putting up a second, new building on the Fairfield County campus of its U.S. headquarters -- this one a $65 million structure to house its research and development operations.
Boehringer officials and other dignitaries were on hand Monday to break ground for the 72,000-square-foot R&D building set to open in 2014. Torcon Inc., of Red Bank, N.J., is the general contractor.
It will handle production of active pharmaceutical ingredients used in early development activities, the closely held company says. Products developed there, if approved, move on to its full-scale R&D facilities in Ohio and Virginia, as well as Germany and Italy.
In August, it broke ground on a $42.5 million Safety Assessment Building also on the 294-acre campus that straddles the towns of Ridgefield and Danbury.
That building, when completed in 2013, will provide more than 63,000 square feet of space for non-clinical safety studies in development, as well as studies for research, the paper said Tuesday on its Web site.
In all, Boehringer is investing $350 million in its U.S. operations.
Last summer, its animal health business, Boehringer Ingelheim VetMedica Inc., its new $89 million vaccine research facility in Sioux Center, Iowa, one of three special vaccine research buildings it will build there. The company also announced a $100 million expansion of its biological manufacturing facility in St. Joseph, Mo.
In September, Boehringer Ingelheim Roxane Inc. opened a new $50 million High Containment Operations facility in Columbus, Ohio, to meet a growing market demand for high potency and oncology products.